{
  "doc_id": "SORAFENIB-SANDOZ-ROZHODNUTI-SSET-243488-24_NPM",
  "chunks": [
    {
      "text": "PRO KONTROLU LÉČIV 100 41 Praha 10 Fax: +420 271 732 377 Web: To the Minister for Health, Welfare and Sport Box 20350 2500 EJ 'S-GRAVENHAGE Your Letter of Attribution Date 6 December 2007 Farmatec/FZ-2819284 25 February 2008 Our Attribution Treated by Reference No PAK/28003871 mw Dr P.K. Cheung (020) 797 88 10 Subject Assessment of sorafenib in hepatocellular carcinoma Dear Mr Klink, In your letter of 6 December 2007, you requested the Health Insurance Council (HIC) to assess whether Nexavar® (sorafenib) is interchangeable with a medicine included in the insured package. If not, you are requested to assess the therapeutic value of this medicine for the indication for which reimbursement has been requested.",
      "metadata": {
        "doc_id": "SORAFENIB-SANDOZ-ROZHODNUTI-SSET-243488-24_NPM",
        "heading": "",
        "start_page": 1,
        "end_page": 1,
        "created_date": "2024",
        "country": "CZ",
        "source_type": "hta_submission",
        "original_file_path": "hcc/HTA submissions/CZ/SORAFENIB-SANDOZ-ROZHODNUTI-SSET-243488-24_NPM_cleaned.json",
        "split_index": 0,
        "merged": true
      }
    }
  ]
}